Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Late Breaking Abstract - Mesenchymal stromal cells as a salvage treatment for persistent ARDS

Haijin Lyu, Jianrong Liu, Xiaomeng Yi, Xiaofeng Yuan, Yuling An, Xuxia Wei, Yanhong Wang, Ying Xian, Huimin Yi
European Respiratory Journal 2020 56: 3720; DOI: 10.1183/13993003.congress-2020.3720
Haijin Lyu
1Surgical and Transplant Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lvhaijin@mai.sysu.edu.cn
Jianrong Liu
1Surgical and Transplant Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaomeng Yi
1Surgical and Transplant Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaofeng Yuan
2General Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuling An
1Surgical and Transplant Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuxia Wei
1Surgical and Transplant Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanhong Wang
3Medical Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Xian
2General Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huimin Yi
1Surgical and Transplant Intensive Care Unit,The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Aims: Mesenchymal stromal cells (MSCs) are promising but with limited safety and efficacy profiles in ARDS. To explore the safety and salvage role of Umbilical Cord derived MSCs (UCMSCs) in persistent ARDS (pARDS) patients, we collected the preliminary data from a single arm prospective study (NCT03608592) in four ICUs of a teaching hospital.

Methods: Moderate to severe ARDS with unimproved oxygenation following 24 hours’ conventional therapies were defined as pARDS. A single dose (1 million/kg) of UCMSCs was infused intravenously. Infusion associated events (IAEs) and clinical outcomes were observed and compared with propensity score matched (PSM) controls.

Results: Twenty-two pARDS with UCMSCs infusion with 1:1 PSM controls were finally analyzed. No prespecified IAEs was observed. Compared with PSM controls, UCMSCs significantly improved P/F, decreased lung injury (Fig1) and reduced adjusted mortality at 60 days (45% vs 55%, HR 0.25, 95% CI 0.08-0.73, P=0.01) and ventilator free days (mean difference 7.5, 95% CI 3-12, P<0.01).

Conclusion: The present data showed the safety and potential survival benefit of a single dose of UCMSCs in persistent ARDS. Larger trials are warranted.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Clinical outcomes in UCMSCs and control group. Student t test for intergroup analysis, *P<0.05, **P<0.01, ***P<0.001. RALE, Radiographic Assessment of Lung Edema score was measured according to the literature [Warren, et.al Thorax 2018, 73 (9):840-846]

  • Treatments
  • Critically ill patients
  • ARDS (Acute Respiratory Distress Syndrome)

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3720.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2020
Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Late Breaking Abstract - Mesenchymal stromal cells as a salvage treatment for persistent ARDS
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Late Breaking Abstract - Mesenchymal stromal cells as a salvage treatment for persistent ARDS
Haijin Lyu, Jianrong Liu, Xiaomeng Yi, Xiaofeng Yuan, Yuling An, Xuxia Wei, Yanhong Wang, Ying Xian, Huimin Yi
European Respiratory Journal Sep 2020, 56 (suppl 64) 3720; DOI: 10.1183/13993003.congress-2020.3720

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Late Breaking Abstract - Mesenchymal stromal cells as a salvage treatment for persistent ARDS
Haijin Lyu, Jianrong Liu, Xiaomeng Yi, Xiaofeng Yuan, Yuling An, Xuxia Wei, Yanhong Wang, Ying Xian, Huimin Yi
European Respiratory Journal Sep 2020, 56 (suppl 64) 3720; DOI: 10.1183/13993003.congress-2020.3720
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Late Breaking Abstract - Temporary Transvenous Diaphragm Neurostimulation in difficult-to-wean mechanically ventilated patients - Results of the RESCUE 2 randomized controlled trial
  • Variation in ventilation management and outcome in ICU patients without ARDS – an IPD metaanalysis of 4 worldwide observational studies
  • Inadequate assessment of patient-ventilator interaction due to suboptimal diaphragm electrical activity signal filtering
Show more Acute critical care

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society